Debiopharm: all 52 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Renal Impairment Pharmacokinetics (PK) Trial of AfabicinNot yet recruitingNCT07758608Phase 1
• A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy AdultsRecruitingNCT07035769Phase 1
• A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)RecruitingNCT06969430Phase 1/2
• A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsRecruitingNCT06930625Phase 3
• A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaRecruitingNCT05765812Phase 1/2
• Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid TumorsRecruitingNCT04855656Phase 1
• Study of RP-6306 With FOLFIRI in Advanced Solid TumorsTerminatedNCT05147350Phase 1Results posted
• Study of RP-6306 With Gemcitabine in Advanced Solid TumorsTerminatedNCT05147272Phase 1Results posted
• Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143CompletedNCT04122625Phase 1/2Results posted
• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)TerminatedNCT03834220Phase 2Results posted
• Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to StaphylococcusTerminatedNCT03723551Phase 2Results posted
• Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C PatientsCompletedNCT02753699Phase 3Results posted
• Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHLCompletedNCT02564744Phase 2Results posted
• Study of Debio 1450 for Bacterial Skin InfectionsCompletedNCT02426918Phase 2Results posted
• Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionCompletedNCT02094443Phase 2Results posted
• Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate CancerCompletedNCT01656161Phase 3Results posted
• Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CTerminatedNCT01500772Phase 3Results posted
• Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious PubertyCompletedNCT01467882Phase 3Results posted
• Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1TerminatedNCT01446250Phase 3Results posted
• Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve ParticipantsCompletedNCT01318694Phase 3Results posted
• Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve ParticipantsCompletedNCT01215643Phase 2Results posted
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous TreatmentCompletedNCT01183169Phase 2Results posted
• Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate CancerCompletedNCT00751790Phase 3Results posted
• A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard TreatmentCompletedNCT00537407Phase 2Results posted
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate CancerCompletedNCT06395753Phase 2
• A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)Active, not recruitingNCT06129539Phase 3
• Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based TherapyTerminatedNCT05815160Phase 1
• A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedNCT05364944Phase 1
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid TumorsTerminatedNCT05109975Phase 1
• A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male ParticipantsCompletedNCT04962724Phase 1
• Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid TumorsTerminatedNCT03968653Phase 1
• A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based TherapyCompletedNCT03270176Phase 1
• A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy SubjectsCompletedNCT03209648Phase 1
• Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement SurgeryCompletedNCT02726438Phase 1
• Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male SubjectsCompletedNCT02595203Phase 1
• A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy VolunteersCompletedNCT02214433Phase 1
• A Single Dose Study of Debio 1450 in Healthy SubjectsCompletedNCT02162199Phase 1
• Debio 1143-201 Dose-finding and Efficacy Phase I/II TrialCompletedNCT02022098Not applicable
• Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy SubjectsCompletedNCT01975337Phase 1
• Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsCompletedNCT01970904Not applicable
• Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) AlterationsTerminatedNCT01948297Phase 1
• Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid MalignanciesTerminatedNCT01930292Phase 1
• Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedNCT01860326Phase 1
• A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]TerminatedNCT01714037Phase 1
• Study of Debio 0932 in Patients With Advanced Solid Tumours or LymphomaCompletedNCT01168752Phase 1
• Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT01078649Phase 1
• Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart FailureWithdrawnNCT00869115Phase 1
• A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsCompletedNCT00854802Not applicable
• Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure PatientsWithdrawnNCT00838253Phase 2
• Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) PatientsCompletedNCT00455767Phase 2
• Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's DiseaseCompletedNCT00423228Not applicable
• Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal BleedingCompletedNCT00331188Phase 3

← Debiopharm overview and focus areas